Johnson & Johnson had gone quiet on the hypertension candidate aprocitentan after lacklustre data last November and now the blow has fallen: the big pharma has returned worldwide rights to the product’s originator, Idorsia Ltd., leaving the Swiss group with a longer wait for approval and little money to get there.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?